12Jan
Sanofi to Acquire Kymab for up to $1.45 Billion
Sanofi announced that it has entered into an agreement to acquire Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics, for an upfront payment of approximately $1.1 billion and up to $350 million upon achievement of certain milestones. The acquisition will give Sanofi full global rights to Kymab’s KY1005, which binds to OX40-Ligand and has the potential to treat a wide variety of...
By:
Goodwin
Related
Reporting Harassment to Third Parties Constitutes Slander - Precedential Decision by Judiciary or R...
Read More >
The use of net asset value finance by private equity firms has spiked under COVID-19 as managers exp...
Read More >
Sixteen State legislators from the greater Bay Area took issue with the residential construction lim...
Read More >
Yesterday, the Department of Labor (DOL) released the final version of its long-anticipated update t...
Read More >
Act No. 2 of October 17, 1961 (Act 2) created a procedural process for the expeditious adjudication ...
Read More >
The COVID-19 pandemic has changed most governments' views on the strategic relevance of the domestic...
Read More >